The clinical observation of hepatic toxicity in hepatitis B virus markers positive cancer patients undergoing chemotherapy

Abstract

Objective To evaluate the liver damage induced by chemotherapy in patients with cancer and positive for hepatitis B virus (HBV) markers.Methods From January 2005 to January 2012,913 cancer patients were treated by chemotherapy including HBV-positive patients (HBV-positive group,288 cases) and HBV-negative patients (HBV-negative group,625 cases).The changes of hepatic function after chemotherapy between two groups were compared.Results The incidence of hepatic toxicity in HBV-positive group was higher than that in HBV-negative group [24.0％ (69/288) vs.11.4％ (71/625)],and there was significant difference between two groups (P＜ 0.01).The incidence of degree 11Ⅲ-Ⅳ hepatic toxicity was 11.4％ (14/123) in HBV-DNA-positive patients and 0.6％ (4/625) in HBV-negative group.In a variety of chemotherapy,there was significant difference in the incidence of hepatic toxicity in TP(paclitaxel +cisplatin),CAF(cyclophosphamide + doxorubicin + fluorouracil),CHOP(cyclophosphamide + doxorubicin +vincristine + prednisone) between two groups (P ＜ 0.05).The incidence of hepatic toxicity was highest in TP,which was 34.6％ (18/52) in HBV-positive group and 16.5％ (20/121) in HBV-negative group.Conclusion HBV infection is associated with higher risk of hepatic toxicity in patients with cancer during chemotherapy. Key words: Hepatitis B virus; Neoplasms; Chemotherapy; Hepatic toxicity